Regimens and Assessment
emesis, nausea, death
METASTASIS
Patients received IMRT and concomitant cisplatin every 3 weeks at 100 mg/mPatients completed a study diary throughout the study to record the degree of nausea, the timing and number of emetic episodes, and the use of rescue therapy. Patients estimated the extent of their nausea using a validated 4-graded scale (none, mild, moderate, or severe).The primary end point was the proportion of patients with sustained complete response (defined as no emesis and no rescue therapy) during CCRT. Secondary end points were the proportion of patients with sustained no emesis, sustained no nausea, sustained no significant nausea (defined as no or mild nausea), and the mean time to first emetic episode during CCRT. Other outcomes included the quality of life and 1-year progression-free survival (PFS), defined as the time from random assignment to locoregional relapse or distant metastasis, or death from any cause.